Role of piperacillin/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli

International Journal of Antimicrobial Agents

Volumn 49, Issue 4, 2017, Pages 410-415

  Yoon, Young Kyung ^a   Kim, Jong Hun ^a   Sohn, Jang Wook ^a   Yang, Kyung Sook ^a   Kim, Min Ja ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Acute pyelonephritis; Ertapenem; ESBL; Escherichia coli; Extended spectrum lactamase; Piperacillin tazobactam

Indexed keywords

ERTAPENEM; IMMUNOSUPPRESSIVE AGENT; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; BETA LACTAM; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION;

ACUTE PYELONEPHRITIS; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CLEARANCE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG TREATMENT FAILURE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; FEMALE; HOSPITAL MORTALITY; HUMAN; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MIC50; MIC90; NONHUMAN; OBSERVATIONAL STUDY; PRESCRIPTION; RETROSPECTIVE STUDY; SEPTIC SHOCK; ADOLESCENT; ANALOGS AND DERIVATIVES; ENZYMOLOGY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; PYELONEPHRITIS; SECRETION (PROCESS); SOUTH KOREA; SURVIVAL ANALYSIS; TREATMENT FAILURE; UNIVERSITY HOSPITAL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; BETA-LACTAMS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; MALE; MIDDLE AGED; PENICILLANIC ACID; PIPERACILLIN; PYELONEPHRITIS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT FAILURE; YOUNG ADULT;

EID: 85014600220     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2016.12.017     Document Type: Article

References (39)

1. [1] Foxman, B., Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Dis Mon 49 (2003), 53–70.
2. [2] Flores-Mireles, A.L., Walker, J.N., Caparon, M., Hultgren, S.J., Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol 13 (2015), 269–284.
3. [3] Hooton, T.M., Clinical practice. Uncomplicated urinary tract infection. N Engl J Med 366 (2012), 1028–1037.
4. [4] Lee, D.S., Choe, H.S., Lee, S.J., Bae, W.J., Cho, H.J., Yoon, B.I., et al. Antimicrobial susceptibility pattern and epidemiology of female urinary tract infections in South Korea, 2010–2011. Antimicrob Agents Chemother 57 (2013), 5384–5393.
5. [5] Lee, K., Kim, M.N., Kim, J.S., Hong, H.L., Kang, J.O., Shin, J.H., et al. Further increases in carbapenem-, amikacin-, and fluoroquinolone-resistant isolates of Acinetobacter spp. and P. aeruginosa in Korea: KONSAR study 2009. Yonsei Med J 52 (2011), 793–802.
6. [6] Ramphal, R., Ambrose, P.G., Extended-spectrum β-lactamases and clinical outcomes: current data. Clin Infect Dis 42:Suppl. 4 (2006), S164–72.
7. [7] Yoon, Y.K., Yang, K.S., Lee, S.E., Kim, H.J., Sohn, J.W., Kim, M.J., Effects of group 1 versus group 2 carbapenems on the susceptibility of Acinetobacter baumannii to carbapenems: a before and after intervention study of carbapenem-use stewardship. PLoS ONE, 9, 2014 e99101.
8. [8] McLaughlin, M., Advincula, M.R., Malczynski, M., Qi, C., Bolon, M., Scheetz, M.H., Correlations of antibiotic use and carbapenem resistance in Enterobacteriaceae. Antimicrob Agents Chemother 57 (2013), 5131–5133.
9. [9] Gupta, K., Hooton, T.M., Naber, K.G., Wullt, B., Colgan, R., Miller, L.G., et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52 (2011), e103–20.
10. [10] Falagas, M.E., Karageorgopoulos, D.E., Extended-spectrum β-lactamase-producing organisms. J Hosp Infect 73 (2009), 345–354.
11. [11] Rodríguez-Baño, J., Navarro, M.D., Retamar, P., Picón, E., Pascual, Á., β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 54 (2012), 167–174.
12. [12] Lo, C.L., Lee, C.C., Li, C.W., Li, M.C., Hsueh, P.R., Lee, N.Y., et al. Fluoroquinolone therapy for bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. J Microbiol Immunol Infect, 2015, 10.1016/j.jmii.2015.08.012.
13. [13] Ng, T.M., Khong, W.X., Harris, P.N., De, P.P., Chow, A., Tambyah, P.A., et al. Empiric piperacillin–tazobactam versus carbapenems in the treatment of bacteraemia due to extended-spectrum β-lactamase-producing Enterobacteriaceae. PLoS ONE, 11, 2016 e0153696.
14. [14] Kanj, S.S., Kanafani, Z.A., Current concepts in antimicrobial therapy against resistant Gram-negative organisms: extended-spectrum β-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc 86 (2011), 250–259.
15. [15] Trivedi, M., Patel, V., Soman, R., Rodriguez, C., Singhal, T., The outcome of treating ESBL infections with carbapenems vs. non carbapenem antimicrobials. J Assoc Physicians India 60 (2012), 28–30.
16. [16] Park, S.H., Choi, S.M., Chang, Y.K., Lee, D.G., Cho, S.Y., Lee, H.J., et al. The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli. J Antimicrob Chemother 69 (2014), 2848–2856.
17. [17] Asakura, T., Ikeda, M., Nakamura, A., Kodera, S., Efficacy of empirical therapy with non-carbapenems for urinary tract infections with extended-spectrum β-lactamase-producing Enterobacteriaceae. Int J Infect Dis 29 (2014), 91–95.
18. [18] Nicolle, L.E., Complicated pyelonephritis: unresolved issues. Curr Infect Dis Rep 9 (2007), 501–507.
19. [19] Gilbert, D.N., Moellering, R.C. Jr, Eliopoulos, G.M., The Sanford guide to antimicrobial therapy 2010. 40th ed, 2010, Antimicrobial Therapy, Inc., Sperryville (VA).
20. [20] Longo, D.L., Fauci, A., Kasper, D., Hauser, S., Jameson, J., Loscalzo, J., Harrison's principles of internal medicine. 18th ed, 2012, McGraw-Hill, New York (NY).
21. [21] Charlson, M., Szatrowski, T.P., Peterson, J., Gold, J., Validation of a combined comorbidity index. J Clin Epidemiol 47 (1994), 1245–1251.
22. [22] Clinical and Laboratory Standards Institute, Performance standards for antimicrobial susceptibility testing; twenty-third informational supplement. Document M100-S23, 2013, CLIS, Wayne, PA.
23. [23] Kim, M.H., Lee, H.J., Park, K.S., Suh, J.T., Molecular characteristics of extended spectrum β-lactamases in Escherichia coli and Klebsiella pneumoniae and the prevalence of qnr in extended spectrum β-lactamase isolates in a tertiary care hospital in Korea. Yonsei Med J 51 (2010), 768–774.
24. [24] Yoo, J.S., Byeon, J., Yang, J., Yoo, J.I., Chung, G.T., Lee, Y.S., High prevalence of extended-spectrum β-lactamases and plasmid-mediated AmpC β-lactamases in Enterobacteriaceae isolated from long-term care facilities in Korea. Diagn Microbiol Infect Dis 67 (2010), 261–265.
25. [25] Yoon, Y.K., Cheong, H.W., Pai, H., Roh, K.H., Kim, J.Y., Park, D.W., et al. Molecular analysis of a prolonged spread of Klebsiella pneumoniae co-producing DHA-1 and SHV-12 β-lactamases. J Microbiol 49 (2011), 363–368.
26. [26] Kang, C.I., Wi, Y.M., Ko, K.S., Chung, D.R., Peck, K.R., Lee, N.Y., et al. Outcomes and risk factors for mortality in community-onset bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli, with a special emphasis on antimicrobial therapy. Scand J Infect Dis 45 (2013), 519–525.
27. [27] Agence Française de Sécurité Sanitaire des Produits de Santé, Diagnostic et antibiothérapie des infections urinaires bactériennes communautaires de l'adulte. SPILF. Available from: http://www.infectiologie.com/UserFiles/File/spilf/recos/infections-urinaires-spilf.pdf, 2015 [Accessed 15 October 2016].
28. [28] Peterson, L.R., Antibiotic policy and prescribing strategies for therapy of extended-spectrum β-lactamase-producing Enterobacteriaceae: the role of piperacillin–tazobactam. Clin Microbiol Infect 14 (2008), 181–184.
29. [29] Kang, C.I., Park, S.Y., Chung, D.R., Peck, K.R., Song, J.H., Piperacillin–tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. J Infect 64 (2012), 533–534.
30. [30] Paterson, D.L., Bonomo, R.A., Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 18 (2005), 657–686.
31. [31] Ofer-Friedman, H., Shefler, C., Sharma, S., Tirosh, A., Tal-Jasper, R., Kandipalli, D., et al. Carbapenems versus piperacillin–tazobactam for bloodstream infections of nonurinary source caused by extended-spectrum β-lactamase-producing Enterobacteriaceae. Infect Control Hosp Epidemiol 36 (2015), 981–985.
32. [32] Gavin, P.J., Suseno, M.T., Thomson, R.B. Jr, Gaydos, J.M., Pierson, C.L., Halstead, D.C., et al. Clinical correlation of the CLSI susceptibility breakpoint for piperacillin–tazobactam against extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella species. Antimicrob Agents Chemother 50 (2006), 2244–2247.
33. [33] López-Cerero, L., Picón, E., Morillo, C., Hernández, J.R., Docobo, F., Pachón, J., et al. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin–clavulanate and piperacillin–tazobactam with extended-spectrum β-lactamase-producing and extended-spectrum β-lactamase-non-producing Escherichia coli isolates. Clin Microbiol Infect 16 (2010), 132–136.
34. [34] Perez, F., Bonomo, R.A., Editorial commentary: bloodstream infection caused by extended-spectrum β-lactamase-producing Gram-negative bacteria: how to define the best treatment regimen?. Clin Infect Dis 60 (2015), 1326–1329.
35. [35] Nogueira Kda, S., Daur, A.V., Reason, I.T., Gales, A.C., Costa, L.M., Cefepime versus extended spectrum β-lactamase-producing Enterobacteriaceae. Braz J Infect Dis 15 (2011), 167–169.
36. [36] Daniel, K.P., Krop, L.C., Piperacillin–tazobactam: a new β-lactam–β-lactamase inhibitor combination. Pharmacotherapy 16 (1996), 149–162.
37. [37] Saltoglu, N., Karali, R., Yemisen, M., Ozaras, R., Balkan, I.I., Mete, B., et al. Comparison of community-onset healthcare-associated and hospital-acquired urinary infections caused by extended-spectrum β-lactamase-producing Escherichia coli and antimicrobial activities. Int J Clin Pract 69 (2015), 766–770.
38. [38] Fong, J.J., Rosé, L., Radigan, E.A., Clinical outcomes with ertapenem as a first-line treatment option of infections caused by extended-spectrum β-lactamase producing Gram-negative bacteria. Ann Pharmacother 46 (2012), 347–352.
39. [39] Efstathiou, S.P., Pefanis, A.V., Tsioulos, D.I., Zacharos, I.D., Tsiakou, A.G., Mitromaras, A.G., et al. Acute pyelonephritis adults: prediction of mortality and failure of treatment. Arch Intern Med 163 (2003), 1206–1212.